ATE537157T1 - Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren - Google Patents

Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren

Info

Publication number: ATE537157T1
Authority: AT; Austria
Prior art keywords: thiazoledindiones; estrogen; alkylated; receptor alpha; substituted phenoxy
Prior art date: 2007-03-07

Application number

AT08731517T

Other languages

English (en)

Inventor

Michael Gaul

Lily Lee Searle

Dionisios Rentzeperis

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-07

Filing date

2008-03-06

Publication date

2011-12-15

2008-03-06 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE537157T1 publication Critical patent/ATE537157T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)

AT08731517T 2007-03-07 2008-03-06 Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren ATE537157T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89345807P	2007-03-07	2007-03-07
PCT/US2008/056018 WO2008109731A2 (en)	2007-03-07	2008-03-06	Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators

Publications (1)

Publication Number	Publication Date
ATE537157T1 true ATE537157T1 (de)	2011-12-15

Family

ID=39720674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08731517T ATE537157T1 (de)	2007-03-07	2008-03-06	Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren

Country Status (26)

Country	Link
US (2)	US8119669B2 (de)
EP (1)	EP2132188B1 (de)
JP (1)	JP2010520307A (de)
KR (1)	KR20090118103A (de)
CN (1)	CN101679326B (de)
AR (1)	AR065656A1 (de)
AT (1)	ATE537157T1 (de)
AU (1)	AU2008222749A1 (de)
BR (1)	BRPI0808662B8 (de)
CA (1)	CA2679965A1 (de)
CL (1)	CL2008000669A1 (de)
CY (1)	CY1112778T1 (de)
DK (1)	DK2132188T3 (de)
EA (1)	EA200970838A1 (de)
ES (1)	ES2377165T3 (de)
HR (1)	HRP20120160T1 (de)
IL (1)	IL200758A0 (de)
MX (1)	MX2009009519A (de)
NZ (1)	NZ579418A (de)
PL (1)	PL2132188T3 (de)
PT (1)	PT2132188E (de)
RS (1)	RS52247B (de)
SI (1)	SI2132188T1 (de)
TW (1)	TW200902507A (de)
WO (1)	WO2008109731A2 (de)
ZA (1)	ZA200906953B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
BRPI0808445A2 (pt) *	2007-03-07	2014-08-05	Janssen Pharmaceutica Nv	TIAZOLIDINADIONAS COMO MODULADORES DE RECEPTOR-a RELACIONADOS COM ESTROGÊNIO
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2698929C (en)	2007-09-14	2016-01-19	Addex Pharma S.A.	1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
CN103342695B (zh)	2007-09-14	2015-04-22	杨森制药有限公司	1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
BRPI0817101A2 (pt)	2007-09-14	2017-05-09	Addex Pharmaceuticals Sa	4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
WO2009062676A2 (en)	2007-11-14	2009-05-22	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2254576B1 (de) *	2008-02-22	2013-08-28	The Ohio State University Research Foundation	Androgen-rezeptor-ablative mittel
WO2010025890A1 (en)	2008-09-02	2010-03-11	Ortho-Mcneil-Janssen Pharmaceuticals, Inc	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en)	2008-10-16	2014-04-15	Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP2373649B1 (de)	2008-11-28	2013-01-23	Janssen Pharmaceuticals, Inc.	Indol- und benzoxazinderivate als modulatoren von metabotropen glutamatrezeptoren
AU2010246609B2 (en)	2009-05-12	2013-09-05	Addex Pharma S.A.	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MX2011011962A (es)	2009-05-12	2012-02-28	Janssen Pharmaceuticals Inc	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP2011057644A (ja) *	2009-09-14	2011-03-24	Sumitomo Chemical Co Ltd	３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物
JP2011057643A (ja) *	2009-09-14	2011-03-24	Sumitomo Chemical Co Ltd	３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物
TW201144303A (en)	2010-02-17	2011-12-16	Janssen Pharmaceutica Nv	Aminothiazolones as estrogen related receptor-α modulators
WO2012062750A1 (en)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814998C (en)	2010-11-08	2019-10-29	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8993591B2 (en)	2010-11-08	2015-03-31	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9056862B2 (en) *	2011-05-10	2015-06-16	National University Corporation Kobe University	Thioxothiazolidine derivative having Ras function inhibitory effect
TW201311679A (zh)	2011-08-04	2013-03-16	Takeda Pharmaceutical	含氮雜環化合物
CN102949364A (zh) *	2011-08-30	2013-03-06	天津药物研究院	一种含有效成分盐酸维拉佐酮的缓释片
JP5865995B2 (ja)	2012-03-26	2016-02-17	日本ケミファ株式会社	骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
EP2909333A1 (de) *	2012-10-17	2015-08-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur vorhersage und behandlung von knochenmetastasen bei patienten mit prostatakrebs
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3632428A1 (de)	2013-09-25	2020-04-08	Nippon Chemiphar Co., Ltd.	Zaltoprofen zur verwendung bei der prophylaktischen oder therapeutischen behandlung von riesenzelltumoren in knochen und weichteilen oder von chondrosarkom
SMT202100103T1 (it)	2014-01-21	2021-03-15	Janssen Pharmaceutica Nv	Combinazione comprendente modulatori allosterici postivi del recettore glutammatergico metabotropico sottotipo 2 e loro utilizzo
HUE045610T2 (hu)	2014-01-21	2020-01-28	Janssen Pharmaceutica Nv	2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en)	2014-08-11	2018-09-11	Yale University	Estrogen-related receptor alpha based protac compounds and associated methods of use
RU2018120330A (ru)	2015-11-02	2019-12-04	Йейл Юниверсити	Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
US20210228594A1 (en) *	2018-08-22	2021-07-29	Christina Theodoris	Methods for treating cardiac valve disease
CN112538038B (zh) *	2019-09-20	2022-05-20	暨南大学	2-吲哚酮类ERRα反向激动剂及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5037842A (en)	1990-06-05	1991-08-06	Pfizer Inc.	Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JP2001072592A (ja)	1999-07-01	2001-03-21	Kyowa Hakko Kogyo Co Ltd	テロメラーゼ阻害剤
CN1321153A (zh) *	1999-07-01	2001-11-07	杰龙公司	端粒酶抑制剂及其使用方法
AU2001257022B2 (en)	2000-04-13	2005-02-03	Mayo Foundation For Medical Education And Research	Abeta 42 lowering agents
DE10131899A1 (de)	2001-07-04	2003-02-27	Boehringer Ingelheim Pharma	In vitro-Screening-Assay für gamma-Secretase
CA2483771A1 (en) *	2002-04-30	2004-03-25	Merck & Co., Inc.	Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
EP1398029A1 (de)	2002-09-10	2004-03-17	LION Bioscience AG	3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US20080313061A1 (en)	2004-06-30	2008-12-18	Paysetter Pte Ltd	System and Method for Facilitating Transfer of Physical Money and/or Credit
AU2005275279A1 (en)	2004-07-14	2006-02-23	Janssen Pharmaceutica N.V.	Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
EP1805154A4 (de)	2004-10-22	2009-11-25	Exelixis Inc	Pharmazeutische zusammensetzungen

2008
- 2008-03-06 CA CA002679965A patent/CA2679965A1/en not_active Abandoned
- 2008-03-06 EP EP08731517A patent/EP2132188B1/de active Active
- 2008-03-06 CN CN2008800153616A patent/CN101679326B/zh not_active Expired - Fee Related
- 2008-03-06 JP JP2009552883A patent/JP2010520307A/ja active Pending
- 2008-03-06 KR KR1020097020832A patent/KR20090118103A/ko not_active Application Discontinuation
- 2008-03-06 TW TW097107936A patent/TW200902507A/zh unknown
- 2008-03-06 SI SI200830561T patent/SI2132188T1/sl unknown
- 2008-03-06 DK DK08731517.2T patent/DK2132188T3/da active
- 2008-03-06 BR BRPI0808662A patent/BRPI0808662B8/pt not_active IP Right Cessation
- 2008-03-06 NZ NZ579418A patent/NZ579418A/en not_active IP Right Cessation
- 2008-03-06 PT PT08731517T patent/PT2132188E/pt unknown
- 2008-03-06 CL CL2008000669A patent/CL2008000669A1/es unknown
- 2008-03-06 RS RS20120106A patent/RS52247B/en unknown
- 2008-03-06 AU AU2008222749A patent/AU2008222749A1/en not_active Abandoned
- 2008-03-06 WO PCT/US2008/056018 patent/WO2008109731A2/en active Application Filing
- 2008-03-06 US US12/043,291 patent/US8119669B2/en not_active Expired - Fee Related
- 2008-03-06 PL PL08731517T patent/PL2132188T3/pl unknown
- 2008-03-06 MX MX2009009519A patent/MX2009009519A/es active IP Right Grant
- 2008-03-06 EA EA200970838A patent/EA200970838A1/ru unknown
- 2008-03-06 AT AT08731517T patent/ATE537157T1/de active
- 2008-03-06 ES ES08731517T patent/ES2377165T3/es active Active
- 2008-03-07 AR ARP080100963A patent/AR065656A1/es not_active Application Discontinuation
2009
- 2009-09-06 IL IL200758A patent/IL200758A0/en unknown
- 2009-10-06 ZA ZA2009/06953A patent/ZA200906953B/en unknown
2012
- 2012-01-10 US US13/346,808 patent/US9034852B2/en not_active Expired - Fee Related
- 2012-02-17 HR HR20120160T patent/HRP20120160T1/hr unknown
- 2012-03-07 CY CY20121100232T patent/CY1112778T1/el unknown

Also Published As

Publication number	Publication date
US8119669B2 (en)	2012-02-21
CN101679326B (zh)	2012-12-12
US20080286265A1 (en)	2008-11-20
CL2008000669A1 (es)	2008-11-03
US20120108571A1 (en)	2012-05-03
EP2132188A2 (de)	2009-12-16
BRPI0808662B1 (pt)	2020-09-29
HRP20120160T1 (hr)	2012-03-31
CN101679326A (zh)	2010-03-24
WO2008109731A2 (en)	2008-09-12
IL200758A0 (en)	2010-05-17
CA2679965A1 (en)	2008-09-12
AU2008222749A1 (en)	2008-09-12
ZA200906953B (en)	2010-12-29
CY1112778T1 (el)	2016-02-10
DK2132188T3 (da)	2012-02-27
SI2132188T1 (sl)	2012-04-30
PT2132188E (pt)	2012-02-13
BRPI0808662A2 (pt)	2014-08-26
RS52247B (en)	2012-10-31
TW200902507A (en)	2009-01-16
BRPI0808662B8 (pt)	2021-05-25
WO2008109731A3 (en)	2008-11-27
AR065656A1 (es)	2009-06-24
EA200970838A1 (ru)	2010-02-26
NZ579418A (en)	2012-01-12
JP2010520307A (ja)	2010-06-10
ES2377165T3 (es)	2012-03-23
MX2009009519A (es)	2009-11-18
PL2132188T3 (pl)	2012-05-31
KR20090118103A (ko)	2009-11-17
US9034852B2 (en)	2015-05-19
EP2132188B1 (de)	2011-12-14

Publication	Publication Date	Title
ATE537157T1 (de)	2011-12-15	Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
ATE538091T1 (de)	2012-01-15	Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
DE602007006531D1 (de)	2010-06-24	Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
DK2262808T3 (da)	2013-11-04	Chemokinreceptormodulatorer
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
DE602008003116D1 (de)	2010-12-02	8-oxychinolinderivate als modulatoren des bradykinin-b2-rezeptors
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
BR112012008159A2 (pt)	2016-03-01	moduladores de receptor canabinoide
BRPI0921815A2 (pt)	2018-10-09	compostos receptores de apj
ATE509022T1 (de)	2011-05-15	Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
ATE542825T1 (de)	2012-02-15	Substituierte piperidino-dihydrothienopyrimidine
FI20070766A0 (fi)	2007-10-11	Hissijärjestelmä
FI20070903L (fi)	2009-05-27	Hissijärjestelmä
DE602007008222D1 (de)	2010-09-16	Diazepanderivate als modulatoren von chemokinrezeptoren
EP2421370A4 (de)	2012-12-12	2-alkylpiperidin-mglur5-rezeptormodulatoren
DK2297100T3 (da)	2012-12-17	Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
BRPI0910118A2 (pt)	2015-12-29	antagonistas de receptores do glucagon
BRPI0907122A2 (pt)	2015-07-14	Piridoindóis (1-azinona) substituídos
BRPI0908548A2 (pt)	2015-09-29	suporte de lança
ATE547407T1 (de)	2012-03-15	Alkylthiopyrimidine als crth2-antagonisten
BRPI0822061A2 (pt)	2015-06-23	Moduladores do receptor canabinoide
ATE477243T1 (de)	2010-08-15	2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE512589T1 (de)	2011-07-15	Dihydrochinolinone als ektoparasitizide
ATE515503T1 (de)	2011-07-15	Antiparasitische benzofuranmittel
ATE518843T1 (de)	2011-08-15	Pyrimidinyl-piperazine als dopamin d3/d2- rezeptorliganden